Intended for healthcare professionals


NICE recommends oral treatment for preventing episodic migraine

BMJ 2023; 381 doi: (Published 31 May 2023) Cite this as: BMJ 2023;381:p1249
  1. Jacqui Wise
  1. Kent

The first oral treatment for the prevention of migraines has been recommended by the National Institute for Health and Care Excellence (NICE) in draft guidance.1

Rimegepant (Vydura) is recommended for preventing episodic migraine in adults who have at least four and fewer than 15 migraine attacks a month, and where at least three preventative treatments have previously failed. Currently, preventative treatments used to treat migraine, which include erenumab, fremanezumab, and galcanezumab, are all injections. Rimegepant may be more …

View Full Text

Log in

Log in through your institution


* For online subscription